-
Mashup Score: 0
The published data are from the pivotal CheckMate 274 trial and are currently being reviewed by the FDA for a potential approval of nivolumab in this setting.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1Around the Practice – July 2021 Live Case Event - 1448233 - 3 year(s) ago
Wed, Jul 21, 2021 5:00 PM EDT (9:00 PM GMT) 1 hour Join us for the July installment of Around the Practice where we will focus on Bladder Cancer. Our virtual monthly GU oncology Live Case Event is presented in partnership with LUGPA. Each month, we feature leading experts representing…
Source: globalmeet.webcasts.comCategories: Latest Headlines, UrologyTweet-
Tune in tomorrow for a live bladder cancer patient case review for lessons you can directly apply to clinical practice. Register today: https://t.co/KkPgCMYNfl #urology #urologist #bladdercancer #gucm #urooncology #LUGPA https://t.co/JH26rURMBJ
-
-
Mashup Score: 0Around the Practice – July 2021 Live Case Event - 1448233 - 3 year(s) ago
Wed, Jul 21, 2021 5:00 PM EDT (9:00 PM GMT) 1 hour Join us for the July installment of Around the Practice where we will focus on Bladder Cancer. Our virtual monthly GU oncology Live Case Event is presented in partnership with LUGPA. Each month, we feature leading experts representing…
Source: globalmeet.webcasts.comCategories: Latest Headlines, UrologyTweet-
Tune in tomorrow for a live bladder cancer patient case review for lessons you can directly apply to clinical practice. Register today: https://t.co/KkPgCMYNfl #urology #urologist #bladdercancer #gucm #urooncology #LUGPA https://t.co/h7lhotgUwF
-
-
Mashup Score: 0
Adjuvant pembrolizumab reduced the risk of disease recurrence or death versus placebo in the phase 3 KEYNOTE-564 trial, but overall survival data are still immature.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Adjuvant pembrolizumab arises as new RCC option, but OS data await https://t.co/mC92u1MoK3 #kcsm #gucm #urology #urologist #kidneycancer #oncology
-
-
Mashup Score: 0
Adjuvant pembrolizumab reduced the risk of disease recurrence or death versus placebo in the phase 3 KEYNOTE-564 trial, but overall survival data are still immature.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Adjuvant pembrolizumab arises as new RCC option, but OS data await https://t.co/mC92u23ZBB #kcsm #gucm #urology #urologist #kidneycancer #oncology
-
-
Mashup Score: 0
Adjuvant pembrolizumab reduced the risk of disease recurrence or death versus placebo in the phase 3 KEYNOTE-564 trial, but overall survival data are still immature.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Adjuvant pembrolizumab arises as new RCC option, but OS data await https://t.co/mC92u23ZBB #kcsm #gucm #urology #urologist #kidneycancer #oncology
-
-
Mashup Score: 0
Adjuvant pembrolizumab reduced the risk of disease recurrence or death versus placebo in the phase 3 KEYNOTE-564 trial, but overall survival data are still immature.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Adjuvant pembrolizumab arises as new RCC option, but OS data await https://t.co/mC92u1MoK3 #kcsm #gucm #urology #urologist #kidneycancer #oncology
-
-
Mashup Score: 0
Adjuvant pembrolizumab reduced the risk of disease recurrence or death versus placebo in the phase 3 KEYNOTE-564 trial, but overall survival data are still immature.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Adjuvant pembrolizumab arises as new RCC option, but OS data await https://t.co/mC92u23ZBB #kcsm #gucm #urology #urologist #kidneycancer #oncology
-
-
Mashup Score: 0
Adjuvant pembrolizumab reduced the risk of disease recurrence or death versus placebo in the phase 3 KEYNOTE-564 trial, but overall survival data are still immature.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Adjuvant pembrolizumab arises as new RCC option, but OS data await https://t.co/mC92u23ZBB #kcsm #gucm #urology #urologist #kidneycancer #oncology
-
-
Mashup Score: 0
Adjuvant pembrolizumab reduced the risk of disease recurrence or death versus placebo in the phase 3 KEYNOTE-564 trial, but overall survival data are still immature.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Adjuvant pembrolizumab arises as new RCC option, but OS data await https://t.co/mC92u1MoK3 #kcsm #gucm #urology #urologist #kidneycancer #oncology #EAU21 @Uroweb
-
Adjuvant nivolumab data published in NEJM show DFS benefit in bladder cancer https://t.co/IeYfSvsrpg #bladdercancer #gucm #urooncology #urology #urologist